CN114316085A - 一种顺式透明质酸六糖及其制备方法和用途 - Google Patents
一种顺式透明质酸六糖及其制备方法和用途 Download PDFInfo
- Publication number
- CN114316085A CN114316085A CN202111575677.4A CN202111575677A CN114316085A CN 114316085 A CN114316085 A CN 114316085A CN 202111575677 A CN202111575677 A CN 202111575677A CN 114316085 A CN114316085 A CN 114316085A
- Authority
- CN
- China
- Prior art keywords
- cis
- compound
- hyaluronic acid
- formula
- glucopyranosyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 36
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000036039 immunity Effects 0.000 claims abstract 2
- 235000013305 food Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 4
- 230000030833 cell death Effects 0.000 claims description 3
- 239000003223 protective agent Substances 0.000 claims description 2
- 239000003009 skin protective agent Substances 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000036576 dermal application Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000091 immunopotentiator Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 238000005516 engineering process Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000004611 spectroscopical analysis Methods 0.000 abstract description 3
- 230000006907 apoptotic process Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 239000000413 hydrolysate Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000000362 1H--1H nuclear Overhauser enhancement spectroscopy Methods 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 229940099552 hyaluronan Drugs 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 2
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- 150000003214 pyranose derivatives Chemical group 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 238000002223 1H--13C heteronuclear multiple bond coherence Methods 0.000 description 1
- 241000227129 Aconitum Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- -1 DEPT (modified carbon Chemical class 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008481 normal tissue growth Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108010022457 polysaccharide peptide Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
位置 | β构型(ppm) | α构型(ppm) | VI(ppm) | |
C<sub>1</sub> | 97.40 | 93.72 | 91.01 | |
C<sub>2</sub> | 58.29 | 55.65 | 55.93 | |
C<sub>3</sub> | 85.02 | 82.56 | 82.65 | |
C<sub>4</sub> | 71.11 | 71.12 | 71.26 | |
C<sub>5</sub> | 78.05 | 73.93 | 73.53 | |
C<sub>6</sub> | 63.40 | 63.24 | 66.07 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111575677.4A CN114316085B (zh) | 2021-12-22 | 2021-12-22 | 一种顺式透明质酸六糖及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111575677.4A CN114316085B (zh) | 2021-12-22 | 2021-12-22 | 一种顺式透明质酸六糖及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114316085A true CN114316085A (zh) | 2022-04-12 |
CN114316085B CN114316085B (zh) | 2023-06-02 |
Family
ID=81054283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111575677.4A Active CN114316085B (zh) | 2021-12-22 | 2021-12-22 | 一种顺式透明质酸六糖及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114316085B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101229186A (zh) * | 2000-07-07 | 2008-07-30 | 生化学工业株式会社 | 透明质酸低聚糖级分及含有该物质的药品 |
EP2031053A1 (en) * | 2007-08-31 | 2009-03-04 | The University Of Queensland | Production of HA |
US20150291706A1 (en) * | 2012-11-27 | 2015-10-15 | Contipro Biotech S.R.O. | Photoreactive Derivative of Hyaluronic Acid, Method of Preparation Thereof, 3D.Crosslinked Derivative of Hyaluronic Acid, Method of Preparation and Use Thereof |
CN109517012A (zh) * | 2018-11-13 | 2019-03-26 | 华熙福瑞达生物医药有限公司 | 一种高纯度透明质酸寡糖的制备方法 |
CN110331178A (zh) * | 2019-06-27 | 2019-10-15 | 青岛海洋生物医药研究院股份有限公司 | 一种酶切法制备小分子透明质酸的方法及所得小分子透明质酸与其应用 |
-
2021
- 2021-12-22 CN CN202111575677.4A patent/CN114316085B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101229186A (zh) * | 2000-07-07 | 2008-07-30 | 生化学工业株式会社 | 透明质酸低聚糖级分及含有该物质的药品 |
EP2031053A1 (en) * | 2007-08-31 | 2009-03-04 | The University Of Queensland | Production of HA |
US20150291706A1 (en) * | 2012-11-27 | 2015-10-15 | Contipro Biotech S.R.O. | Photoreactive Derivative of Hyaluronic Acid, Method of Preparation Thereof, 3D.Crosslinked Derivative of Hyaluronic Acid, Method of Preparation and Use Thereof |
CN109517012A (zh) * | 2018-11-13 | 2019-03-26 | 华熙福瑞达生物医药有限公司 | 一种高纯度透明质酸寡糖的制备方法 |
CN110331178A (zh) * | 2019-06-27 | 2019-10-15 | 青岛海洋生物医药研究院股份有限公司 | 一种酶切法制备小分子透明质酸的方法及所得小分子透明质酸与其应用 |
Non-Patent Citations (3)
Title |
---|
DINENE L ET AL: "hyaluronic acid synthesis operon (has) expression in group a streptococci", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 31, pages 18452 - 18458 * |
张宪真;王宝中;: "透明质酸寡糖调节A549/DDP多药耐药作用的研究", 现代肿瘤医学, no. 08, pages 17 - 19 * |
雷曦: "透明质酸降解菌的筛选及其裂解酶的研究", 中国优秀硕士论文全文数据库 基础科学辑, no. 01, pages 1 - 115 * |
Also Published As
Publication number | Publication date |
---|---|
CN114316085B (zh) | 2023-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | Structure, bioactivities and applications of the polysaccharides from Tremella fuciformis mushroom: A review | |
Sun et al. | Physicochemical properties and immunological activities of polysaccharides from both crude and wine-processed Polygonatum sibiricum | |
Wu et al. | Comparison of the structural characterization and biological activity of acidic polysaccharides from Cordyceps militaris cultured with different media | |
Wang et al. | Anti-diabetic activity evaluation of a polysaccharide extracted from Gynostemma pentaphyllum | |
Ru et al. | Structural characterization, hypoglycemic effects and mechanism of a novel polysaccharide from Tetrastigma hemsleyanum Diels et Gilg | |
Zhang et al. | Inhibition of α-glucosidase by polysaccharides from the fruit hull of Camellia oleifera Abel | |
Shashidhar et al. | Functional polysaccharides from medicinal mushroom Cordyceps sinensis as a potent food supplement: extraction, characterization and therapeutic potentials–a systematic review | |
Wu et al. | Extraction, structure and bioactivities of the polysaccharides from Fructus corni | |
CN114874344B (zh) | 青稞嫩叶碱提多糖的制备方法及其应用 | |
Obaroakpo et al. | Bioactive assessment of the antioxidative and antidiabetic activities of oleanane triterpenoid isolates of sprouted quinoa yoghurt beverages and their anti-angiogenic effects on HUVECS line | |
KR101578581B1 (ko) | 신종균 크리세오박테리움 thg-c4-1 및 이를 이용한 지페노사이드 17 생산 방법 | |
CN106581090B (zh) | 一种杨梅素提取物、包含其的药物组合物及其用途 | |
JP2008212137A (ja) | 生物転換法を利用したペリヌスリンテウス菌糸体の液体培養による人参からの新規のジンセノサイド製造方法 | |
CN110218200B (zh) | 一种红树内生真菌中环缩肽化合物及其制备方法与应用 | |
KR20120075214A (ko) | 곤충유래 헤파린대체 제제 조성물의 제조방법 및 이의 용도 | |
CN114316085A (zh) | 一种顺式透明质酸六糖及其制备方法和用途 | |
KR20130043648A (ko) | 곤충유래 헤파린대체 제제 조성물의 제조방법 및 이의 용도 | |
CN105949272B (zh) | 魏察酸浆苦素y及提取方法及用途 | |
CN109232753A (zh) | 一种华美牛肝菌多糖bsf-x及其制备方法与应用 | |
KR20140004036A (ko) | 뒤영벌 류의 알코올 추출물을 유효성분으로 포함하는 혈관신생에 의한 질환의 예방 및 치료용 조성물 | |
CN108892651B (zh) | 一种混源萜二聚体类化合物及其药物组合物和其应用 | |
CN107281255B (zh) | 刺槐叶活性部位及其制备方法和应用 | |
CN111184710A (zh) | 一种环酚的应用和制备方法 | |
CN103638055A (zh) | 拟黑多刺蚁提取物及其和抗真菌医药用途 | |
CN108997473A (zh) | 一种非海参烷型海参皂苷及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DD01 | Delivery of document by public notice |
Addressee: Yang Ming Document name: Notification of qualified procedures |
|
DD01 | Delivery of document by public notice | ||
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231214 Address after: Room A00031, 2nd Floor, Room 215, Haikou Pharmaceutical Valley Biomedical Innovation Complex, Building 7, Haixin Lidu, No. 288 Nanhai Avenue, National High tech Industrial Development Zone, Haikou City, Hainan Province, 570100 Patentee after: Sanyuan Industry Finance (Hainan) Technology Partnership Enterprise (L.P.) Address before: Room 1402, building 4, Wuli, xiaoyueyuan, Fengtai District, Beijing 100072 Patentee before: BEIJING TUOLIN MEDICINE SCIENCE AND TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240527 Address after: Room A00052, 2nd Floor, Room 215, Haikou Pharmaceutical Valley Biomedical Innovation Complex, Building 7, Haixin Lidu, No. 288 Nanhai Avenue, National High tech Industrial Development Zone, Haikou City, Hainan Province, 570100 Patentee after: Tianzhuo (Hainan) Investment Co.,Ltd. Country or region after: China Address before: Room A00031, 2nd Floor, Room 215, Haikou Pharmaceutical Valley Biomedical Innovation Complex, Building 7, Haixin Lidu, No. 288 Nanhai Avenue, National High tech Industrial Development Zone, Haikou City, Hainan Province, 570100 Patentee before: Sanyuan Industry Finance (Hainan) Technology Partnership Enterprise (L.P.) Country or region before: China |
|
TR01 | Transfer of patent right |